Summit Trail Advisors LLC Has $3.33 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Summit Trail Advisors LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,378 shares of the medical research company's stock after purchasing an additional 1,214 shares during the quarter. Summit Trail Advisors LLC's holdings in Thermo Fisher Scientific were worth $3,329,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Ameriprise Financial Inc. raised its holdings in Thermo Fisher Scientific by 32.2% during the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock worth $1,372,157,000 after purchasing an additional 604,895 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,443,937 shares of the medical research company's stock valued at $1,511,746,000 after purchasing an additional 61,017 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Thermo Fisher Scientific by 1.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,740,482 shares of the medical research company's stock valued at $962,482,000 after buying an additional 20,075 shares in the last quarter. Unisphere Establishment boosted its stake in shares of Thermo Fisher Scientific by 7.1% during the 2nd quarter. Unisphere Establishment now owns 1,500,000 shares of the medical research company's stock worth $829,500,000 after acquiring an additional 100,000 shares in the last quarter. Finally, International Assets Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 76,051.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company's stock worth $876,152,000 after acquiring an additional 1,414,556 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TMO shares. Bank of America raised their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research report on Monday, September 16th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company's stock, valued at $7,134,197.76. This represents a 13.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 in the last 90 days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $2.84 during trading hours on Friday, hitting $513.26. 1,833,539 shares of the company's stock traded hands, compared to its average volume of 1,746,299. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52 week low of $480.57 and a 52 week high of $627.88. The company has a market cap of $196.32 billion, a price-to-earnings ratio of 32.18, a price-to-earnings-growth ratio of 3.41 and a beta of 0.79. The company's fifty day simple moving average is $575.70 and its two-hundred day simple moving average is $580.20.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business's revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.69 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.